555 related articles for article (PubMed ID: 16488654)
1. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
Chamilos G; Kontoyiannis DP
Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
[TBL] [Abstract][Full Text] [Related]
2. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
3. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
4. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.
Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2005 Nov; 56(5):887-92. PubMed ID: 16188916
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
6. Aspergillus species intrinsically resistant to antifungal agents.
Van Der Linden JW; Warris A; Verweij PE
Med Mycol; 2011 Apr; 49 Suppl 1():S82-9. PubMed ID: 20662634
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
8. Antifungal treatment in pediatric patients.
Zaoutis TE; Benjamin DK; Steinbach WJ
Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
10. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
11. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.
Verweij PE; Howard SJ; Melchers WJ; Denning DW
Drug Resist Updat; 2009 Dec; 12(6):141-7. PubMed ID: 19879181
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
13. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
Howard SJ; Arendrup MC
Med Mycol; 2011 Apr; 49 Suppl 1():S90-5. PubMed ID: 20795765
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility testing in Aspergillus species: an update.
Lass-Flörl C
Future Microbiol; 2010 May; 5(5):789-99. PubMed ID: 20441550
[TBL] [Abstract][Full Text] [Related]
15. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.
Amorim A; Guedes-Vaz L; Araujo R
Int J Antimicrob Agents; 2010 Apr; 35(4):396-9. PubMed ID: 20138740
[TBL] [Abstract][Full Text] [Related]
17. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
19. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
Steinbach WJ; Singh N; Miller JL; Benjamin DK; Schell WA; Heitman J; Perfect JR
Antimicrob Agents Chemother; 2004 Dec; 48(12):4922-5. PubMed ID: 15561883
[TBL] [Abstract][Full Text] [Related]
20. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
Escribano P; Peláez T; Recio S; Bouza E; Guinea J
Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
